Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | CTH | P32929 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.30 |
| ▸ | SCN1A | P35498 | 2/20 | 0.30 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.30 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.30 |
| ▸ | DRD1 | P21728 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023599 | 0.79 | ADRB2 (0.33) | LMNA | |
| SCHEMBL5015575 | 0.79 | — | — | |
| SCHEMBL5014121 | 0.74 | — | — | |
| SCHEMBL9823681 | 0.72 | — | — | |
| Methyl Alcohol SCHEMBL931967 | 0.69 | NOS3 (0.39) | HTR2ACTHSLC6A4HRH3HTR2C | |
| SCHEMBL2644531 | 0.68 | NOS3 (0.41) | HTR2ACTHSLC6A4HRH3HTR2C | |
| SCHEMBL2645752 | 0.68 | — | — | |
| SCHEMBL31234346 | 0.68 | — | — | |
| SCHEMBL16921699 | 0.67 | CTH (0.38) | CTHHRH3 | |
| SCHEMBL9670705 | 0.66 | HTR2A (0.55) | HRH1HTR2ACHRM2SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451286-B1 | 4- AND 5 SUBSTITUTED 1,2,3- TRIAZOLE MOIETIES WITH AT LEAST ONE REMOTE POLYMERIZABLE MOIETY AND POLYMERS THEREOF | ISP INVESTMENTS INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-8993698-B2 | 4- and 5 substituted 1,2,3-triazole moieties with at least one remote polymerizable moiety and polymers thereof | ISP INVESTMENTS INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20120142846-A1 | 4- AND 5 SUBSTITUTED 1,2,3-TRIAZOLE MOIETIES WITH AT LEAST ONE REMOTE POLYMERIZABLE MOIETY AND POLYMERS THEREOF | AVOCA LLC | 2012-06-07 | — | — | US | disclosed |
| EP-2451286-A1 | 4- AND 5 SUBSTITUTED 1,2,3- TRIAZOLE MOIETIES WITH AT LEAST ONE REMOTE POLYMERIZABLE MOIETY AND POLYMERS THEREOF | Isp Investments Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011005806-A1 | 4- AND 5 SUBSTITUTED 1,2,3- TRIAZOLE MOIETIES WITH AT LEAST ONE REMOTE POLYMERIZABLE MOIETY AND POLYMERS THEREOF | ISP INVESTMENTS INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142846-A1 | 4- AND 5 SUBSTITUTED 1,2,3-TRIAZOLE MOIETIES WITH AT LEAST ONE REMOTE POLYMERIZABLE MOIETY AND POLYMERS THEREOF | H1-4, NPY4R, RXFP4 | HRH1 1270/4885HTR2A 1288/4885CTH 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.